Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
KTTA - Pasithea Therapeutics Corp.
Market Cap 15.47M P/E - EPS this Y - Ern Qtrly Grth -
Income -16.37M Forward P/E -0.83 EPS next Y - 50D Avg Chg 24.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -4.00%
Dividend N/A Price/Book 0.40 EPS next 5Y - 52W High Chg -62.00%
Recommedations 2.00 Quick Ratio 5.71 Shares Outstanding 1.04M 52W Low Chg 91.00%
Insider Own 23.14% ROA -37.90% Shares Float 761.71K Beta 0.74
Inst Own 2.87% ROE -63.25% Shares Shorted/Prior 419/7.85K Price 0.59
Gross Margin - Profit Margin - Avg. Volume 233,632 Target Price -
Oper. Margin - Earnings Date Aug 13 Volume 39,437 Change 0.39%
Healthcare | Biotechnology | United States
About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Pasithea Therapeutics Corp. News
11/20/24 Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
09/26/24 Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
09/26/24 Sector Update: Health Care Stocks Mixed Late Afternoon
09/26/24 Top Midday Gainers
09/26/24 Why Is Pasithea Therapeutics Stock Surging On Thursday?
09/26/24 Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
09/09/24 Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
09/03/24 Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
08/28/24 Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
06/13/24 Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
05/28/24 Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
04/29/24 Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
06:59 AM Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
02/13/24 Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
01/08/24 Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
01/02/24 Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
12/28/23 Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
STEINMAN LAWRENCE Director Director Jun 02 Buy 0.431 30,000 12,930 1,327,174 06/06/23
Shahinian Eric Other Other Sep 28 Buy 1.17 64,357 75,298 1,788,415 09/30/22
Shahinian Eric Other Other Sep 01 Buy 1.13 88,901 100,458 1,724,058 09/06/22
Shahinian Eric Other Other Aug 29 Buy 1.16 22,828 26,480 1,635,157 08/31/22
Shahinian Eric - - Aug 17 Buy 1.2087 155,773 188,283 1,611,329 08/18/22